Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign Up Log In
All Resources Treatments A-Z Personal Assistant Help Center Crisis
Powered By
Real members of MyMyelomaTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.

Has anyone is of this news I had a friend text this to me this morning https://www.facebook.com/share/r/1FtZJAnuAU/?mibextid=wwXIfr

A MyMyelomaTeam Member asked a question 💭
Chester, VA
22K views · 2.6K reactions | #cancer The FDA approved iberdomide, a CELMoD class pill, in combination with daratumumab/dexamethasone in adults with multiple myeloma who have received at least one prior line of therapy. There was significantly improved minimal residual disease rates. | Blooddocdad
22K views · 2.6K reactions | #cancer The FDA approved iberdomide, a CELMoD class pill, in combination with daratumumab/dexamethasone in adults with multiple myeloma who have received at least one prior line of therapy. There was significantly improved minimal residual disease rates. | Blooddocdad
https://www.facebook.com/share/r/1FtZJAnuAU/?mibextid=wwXIfr
August 14
 · 
Reactions
A MyMyelomaTeam Member

Letitia,
The Multiple Myeloma Research Foundation emailed me the article this morning. It’s a new drug for those whose treatments have failed many times. You should get on their email list. HTTPS://www.themmrf.org
Paula🌹

The MMRF | Multiple Myeloma Research Foundation
The MMRF | Multiple Myeloma Research Foundation
https://www.themmrf.org
August 14
A MyMyelomaTeam Member

Clinical trial results from the pivotal phase 3 EXCALIBER-RRMM trial showed that iberdomide combined with daratumumab and dexamethasone (IberDd) achieved a 41% minimal residual disease (MRD)-negative complete response rate at any time, compared to 21% for the standard comparator arm containing daratumumab, bortezomib, and dexamethasone (P < 0.0001). This deep molecular response formed the primary basis for the FDA's accelerated approval.

August 14
A MyMyelomaTeam Member

Letitia,
Go back to Q & A so more people can see your question.💕
Paula🌹

August 18
A MyMyelomaTeam Member

I was informed Iberdomide (brand name Zenbexus) is an oral cereblon E3 ligase modulator (CELMoD) approved by the U.S. FDA in August 2026. It is used with daratumumab and dexamethasone to treat adults with relapsed or refractory multiple myeloma who have received at least one prior therapy.

Has anyone heard about this new drug and has anyone started this new drug ?

August 17
MyMyelomaTeam

That link leads to a Facebook video, but it's not possible to access or view external links or social media content directly.

If you can share what the news was about, it would be much easier to help figure out if it's relevant to myeloma and whether it's worth paying attention to. Sometimes health news shared on social Show Full Answer

That link leads to a Facebook video, but it's not possible to access or view external links or social media content directly.

If you can share what the news was about, it would be much easier to help figure out if it's relevant to myeloma and whether it's worth paying attention to. Sometimes health news shared on social media can be exciting but needs a closer look before getting too hopeful (or worried!).

August 14

Related Questions

View All

Can light kill cancer cells?

A MyMyelomaTeam Member asked a question 💭
Lake Charles, LA
June 11, 2025

Muscle Spasms and Cramps at Night: Is This a Symptom of Relapsed Myeloma?
Tap Into the Power of Directness: Use "I"
Myeloma and Ethnicity: Is Race a Risk Factor in Multiple Myeloma?
Continue with Facebook
Continue with Google
By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.
Already a member? Log In